Steve Simpson-Yap,Edward De Brouwer,Tomas Kalincik,Nick Rijke,Jan A Hillert,Clare Walton,Gilles Edan,Yves Moreau,Tim Spelman,Lotte Geys,Tina Parciak,Clement Gautrais,Nikola Lazovski,Ashkan Pirmani,Amin Ardeshirdavanai,Lars Forsberg,Anna Glaser,Robert McBurney,Hollie Schmidt,Arnfin B Bergmann,Stefan Braune,Alexander Stahmann,Rodden Middleton,Amber Salter,Robert J Fox,Anneke van der Walt,Helmut Butzkueven,Raed Alroughani,Serkan Ozakbas,Juan I Rojas,Ingrid van der Mei,Nupur Nag,Rumen Ivanov,Guilherme Sciascia do Olival,Alice Estavo Dias,Melinda Magyari,Doralina Brum,Maria Fernanda Mendes,Ricardo N Alonso,Richard S Nicholas,Johana Bauer,Aníbal Sebastián Chertcoff,Anna Zabalza,Georgina Arrambide,Alexander Fidao,Giancarlo Comi,Liesbet Peeters

Abstract:Background and objectives: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results: Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01-2.41; aOR 2.43, 95% CI 1.48-4.02) and ICU admission (aOR 2.30, 95% CI 0.98-5.39; aOR 3.93, 95% CI 1.56-9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29-2.38; aOR 2.76, 95% CI 1.87-4.07) and ICU admission (aOR 2.55, 95% CI 1.49-4.36; aOR 4.32, 95% CI 2.27-8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13-3.07; aOR 2.88, 95% CI 1.68-4.92) and ICU admission (aOR 2.13, 95% CI 0.85-5.35; aOR 3.23, 95% CI 1.17-8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71-17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion: Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.

Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies

Organizing pneumonia and COVID-19

Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders

Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases

Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma

[The impact of COVID-19 in a cohort of patients with systemic sclerosis]

SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era

High Frequency of Autoantibodies in COVID-19 Patients with Central Nervous System Complications: a Multicenter Observational Study

The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders

Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Prolonged COVID-19 Pneumonitis and Severe Lung Injury in a Patient with a History of Diffuse Large B-cell Lymphoma after CAR-T Therapy: Highlighting the Role of Corticosteroids

Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab—Challenging Recognition and Treatment

Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies